In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?
Mario Enrico CanonicoConnie N HessChristopher P CannonPublished in: Current atherosclerosis reports (2023)
Recent randomized clinical trials (RTCs) have demonstrated a beneficial effect of monoclonal antibodies (mAb) PCSK9i prescription in patients with ACS on rapid reduction of low-density lipoprotein cholesterol (LDL-C) and on coronary atherosclerosis assessed by intracoronary imaging. Additionally, the safety profile of mAb PCSK9i was confirmed in all RTCs. Available RCTs show the effectiveness and rapid achievement of LDL-C levels according to American College of Cardiology/American Heart Association and European Society of Cardiology guidelines for ACS patients. However, RCTs addressing cardiovascular outcomes of PCSK9i in-hospital initiation in ACS patients are currently ongoing.
Keyphrases
- acute coronary syndrome
- end stage renal disease
- ejection fraction
- healthcare
- newly diagnosed
- chronic kidney disease
- low density lipoprotein
- systematic review
- cardiovascular disease
- emergency department
- prognostic factors
- coronary artery disease
- clinical trial
- heart failure
- peritoneal dialysis
- high resolution
- randomized controlled trial
- mass spectrometry
- photodynamic therapy
- aortic valve
- percutaneous coronary intervention
- loop mediated isothermal amplification
- quantum dots
- electronic health record